Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of M254 in Healthy Volunteers and ITP Patients
NCT03866577Phase 2Terminated
- Sponsor
- Momenta Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Jun 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 7
01
Overview
A Phase 2 trial of m254 in immune thrombocytopenic purpura (ITP), sponsored by Momenta Pharmaceuticals. Started Dec 2018; status: terminated.
02
Drugs
m254
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT03866577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866577.